scholarly journals Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer

2022 ◽  
Author(s):  
Raquibul Hannan ◽  
Michael Christensen ◽  
Hans Hammers ◽  
Alana Christie ◽  
Brendan Paulman ◽  
...  
Keyword(s):  
Kidney Cancer ◽  
Phase Ii ◽  
Phase Ii Trial

ECOG 1808: Randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 4511-4511 ◽  
Author(s):  
Naomi B. Haas ◽  
Maneka Puligandla ◽  
David F. McDermott ◽  
Janice P. Dutcher ◽  
Judith Manola ◽  
...  
Keyword(s):  
Kidney Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Randomized Phase Ii

scholarly journals Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time

2011 ◽  
pp. 141-142
Author(s):  
Camillo Porta
Keyword(s):  
Kidney Cancer ◽  
Treatment Option ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Line Treatment ◽  
Targeted Agents ◽  
First Line ◽  
Randomized Phase Ii ◽  
Molecular Targeted Agents ◽  
First Line Treatment

Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II trial...

Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time

2011 ◽  
Vol 5 (3) ◽  
pp. 141
Author(s):  
Camillo Porta
Keyword(s):  
Kidney Cancer ◽  
Treatment Option ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Line Treatment ◽  
Targeted Agents ◽  
First Line ◽  
Randomized Phase Ii ◽  
Molecular Targeted Agents ◽  
First Line Treatment

Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II trial...

1326: Phase II Trial of Gemcitabine, Paclitaxel, and Cisplatin in Advanced Transitional Cell Carcinoma

2005 ◽  
Vol 173 (4S) ◽  
pp. 360-360
Author(s):  
Peter E. Clark ◽  
Diana Stindt ◽  
M. Craig Hall ◽  
Michele Harmon ◽  
James F. Lovato ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Transitional Cell
Sign in / Sign up

Export Citation Format

Share Document